Treats Parkinson’s disease (PD). ANDA 201892, held by Chartwell RX. Rasagiline Mesylate.
As of Nov 19, 2026, ANDA 201892 (Rasagiline Mesylate), held by Chartwell RX, was first approved by FDA on Jul 27, 2018, with 1 approved supplement and 0 published complete response letters.
Rasagiline tablets are indicated for the treatment of Parkinson’s disease (PD). Rasagiline tablets, a monoamine oxidase (MAO)-B inhibitor (MAOI), are indicated for the treatment of Parkinson's disease
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 27, 2018 | Original application | Approved | None posted |
| Rasagiline MesylateEQ 0.5MG BASE · tablet;oral | Rasagiline Mesylate | Rx |
| Rasagiline MesylateEQ 1MG BASE · tablet;oral | Rasagiline Mesylate | Rx |
| May 8, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 27, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters